DC Chemicals · Product datasheet

Bleomycin Sulfate — Datasheet

CAT. NO. DC4196

Product page and current package options

ParameterValue
Chemical Name(3-(2'-((3S,6R,7S,8S,11S)-1-(6-amino-2-((S)-3-amino-1-(((S)-2,3-diamino-3-oxopropyl)amino)-3-oxopropyl)-5-methylpyrimidin-4-yl)-3-((R)-(((2R,3S,4S,5S,6S)-3-(((2R,3S,4S,5R,6R)-4-(carbamoyloxy)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4,
CAS No.9041-93-4
SynonymsBLEO; BLM; BLEO cell; BLEO-cell; BLEOcell; Bleolem; Bleomycin sulfate; US brand name: Blenoxane. Blanoxan.
FormulaC55H85N17O25S4
M.Wt1512.62
SMILESO=C(N[C@H](C)[C@@H](O)[C@H](C)C(N[C@H]([C@H](O)C)C(NCCC1=NC(C2=NC=C(C(NCCC[S+](C)C)=O)S2)=CS1)=O)=O)[C@H](NC(C3=C(C)C(N)=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=N3)=O)[C@H](C4=CNC=N4)O[C@H](O[C@H]5CO)[C@H]([C@@H](O)[C@@H]5O)O[C@H]6[C@@H](O)[C@H](OC(N)=O)[C@H](
Purity99.00%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Bleomycin sulfate is a DNA synthesis inhibitor with potent antitumor activity.

In Vitro

Bleomycin (BLM) is chosen as the best-studied micronucleus (MN) inducers in human lymphocytes with different mechanisms of genotoxicity. The most frequent Bleomycin-induced DNA lesions are single and double strand breaks and single apuinic/apyrimidinic sites. At the same time Bleomycin is true radiomimetic compound, resembling almost completely the genetic effect of ionizing radiation[1]. The IC50 value of Bleomycin sulfate for UT-SCC-19A cell line is 4.0±1.3 nM. UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin (BLM); IC50 values are 14.2±2.8 nM and 13.0±1.1 nM, respectively[2]. Bleomycin (BLM) induces a significant increase in the percentage of aberrant cells (i.e., cells showing at least one aberration) and in the frequency of chromosomal aberrations per cell compare with control cultures 18 h after treatment (p<0.05)[3].

In Vivo

A short-range beta-emitting radionuclide combined to Bleomycin (In-111-BLMC) is a tumor-targeting agent in SCCs. Within 35 days the weight of nude mice increases 2.8±0.6g. At 25 and 35 days after tumor inoculations the tumor volumes are 111±51 mm3 and 874±577 mm3, respectively. The calculated doubling time is 3.86±0.76 days. SCC cell lines demonstrate different sensitivity to Bleomycin. Our SCC tumor xenograft model shows a rapid growth proper for radiochemotherapeutic studies using In-111-BLMC. The uptake of In-111-BLMC in vivo has been directly proportional to proliferation activity, and the tumors with high binding capacity could be predicted from animal model dose calculations[2]. At 7 and 14 days after Bleomycin (BLM) treatment, the signal of TGF-β1 is significantly stronger than that of the control group. At 28 days after treatment, the TGF-β1 signal became a little weaker. At 7 and 14 days of Bleomycin plus Dex group, the signal of TGF-β1 is also stronger than that of the control group. However, at 28 days, the TGF-β1 signal become weaker and is a little stronger than the level of control group. All the results are given by comparison of the average IOD value[4].

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation